Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.

Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W; Pramipexole ER Studies Group.

Eur J Neurol. 2014 May;21(5):736-43.

2.

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W.

Eur J Neurol. 2013 Jan;20(1):180-7. doi: 10.1111/j.1468-1331.2012.03822.x. Epub 2012 Jul 31.

PMID:
22845710
3.

Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.

Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):759-66. doi: 10.1212/WNL.0b013e31822affb0. Epub 2011 Aug 10.

PMID:
21832218
4.

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10.

PMID:
21832216
5.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

PMID:
20669317
6.

Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W; Pramipexole ER Studies Group.

Eur J Neurol. 2013 Jan;20(1):50-6. doi: 10.1111/j.1468-1331.2012.03712.x. Epub 2012 Apr 27.

PMID:
22537207
7.

Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.

Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W; Pramipexole ER Study Group.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):174-81. doi: 10.1097/WNF.0b013e31825f77b9.

PMID:
22801294
9.

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.

Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L.

Mov Disord. 2005 May;20(5):602-10.

PMID:
15726540
10.

Pramipexole extended-release: a review of its use in patients with Parkinson's disease.

Frampton JE.

Drugs. 2014 Dec;74(18):2175-90. doi: 10.1007/s40265-014-0322-5. Review.

PMID:
25385556
11.

Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.

Takanashi M, Shimo Y, Hatano T, Oyama G, Hattori N.

Drug Res (Stuttg). 2013 Dec;63(12):639-43. doi: 10.1055/s-0033-1351257. Epub 2013 Jul 24.

PMID:
23884661
12.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group.

Mov Disord. 2010 Oct 30;25(14):2326-32. doi: 10.1002/mds.23262.

PMID:
20669265
13.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S.

CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2.

14.

Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.

Kieburtz K; Parkinson Study Group PramiBID Investigators.

Mov Disord. 2011 Jan;26(1):37-44. doi: 10.1002/mds.23396. Epub 2010 Oct 5.

PMID:
20925067
15.

Pramipexole extended release: in Parkinson's disease.

Chwieduk CM, Curran MP.

CNS Drugs. 2010 Apr;24(4):327-36. doi: 10.2165/11204570-000000000-00000. Review.

PMID:
20297857
16.

Pramipexole extended release in Parkinson's disease.

Hametner EM, Seppi K, Poewe W.

Expert Rev Neurother. 2011 Sep;11(9):1229-34. doi: 10.1586/ern.11.122. Review.

PMID:
21864066
17.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.

Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7.

PMID:
20452823
18.
19.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.

Lancet Neurol. 2013 Aug;12(8):747-55. doi: 10.1016/S1474-4422(13)70117-0. Epub 2013 May 31.

Supplemental Content

Support Center